Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor-β expression in benign prostatic hyperplasia

Prostate

Volumn 46, Issue 1, 2001, Pages 45-51

  Glassman, Deborah T ^a   Chon, Joanna K ^a   Borkowski, Andrew ^a   Jacobs, Stephen C ^a   Kyprianou, Natasha ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

Apoptosis; BPH; Cell proliferation; Finasteride; Terazosin; TGF

Indexed keywords

FINASTERIDE; STEROID 5ALPHA REDUCTASE INHIBITOR; TERAZOSIN; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL POPULATION; CELL PROLIFERATION; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; LIGAND BINDING; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; SYMPTOMATOLOGY; TARGET CELL;

ADRENERGIC ALPHA-ANTAGONISTS; ANTIBODIES, MONOCLONAL; APOPTOSIS; CELL DIVISION; DRUG COMBINATIONS; ENZYME INHIBITORS; FINASTERIDE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; KI-67 ANTIGEN; LINEAR MODELS; MALE; PRAZOSIN; PROSTATE; PROSTATIC HYPERPLASIA; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; TRANSFORMING GROWTH FACTOR BETA;

EID: 0035134750     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0045(200101)46:1<45::AID-PROS1007>3.0.CO;2-U     Document Type: Article

References (34)

1. Clinical and experimental studies of benign prostatic hyperplasia
2. Alpha-adrenergic mechanisms in dynamics of benign prostatic hypertrophy
3. Medical management of benign prostatic hyperplasia with androgen suppression
4. The use of alpha-adrenergic blockers in benign prostatic obstruction
5. Induction of prostatic apoptosis by doxazosin in benign prostatic hyperplasia
6. α1-Adrenoreceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia
7. Activation of programmed cell death in the rat ventral prostate after castration
8. Morphological and hormonal changes in the ventral and dorsolateral prostatic lobes of rats treated with finasteride, a 5-alpha reductase inhibitor
9. Evidence of atrophy and apoptosis in the prostates of men given finasteride
10. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia
11. Dysregulated expression of growth factors and their receptors in the development of prostate cancer: Review article
12. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue
13. Vascular endothelial growth factor is up-regulated in vitro and in vivo by androgens
14. Expression of transforming growth factor-β in the rat ventral prostate during castration-induced programmed cell death
15. Transforming growth factor β1 transduced mouse prostate reconstitutions: II. Induction of apoptosis by doxasozin
16. Receptors for the TGF-β family
17. TGFβ signals through a heteromeric protein kinase receptor complex
18. Transforming growth factor β and cell cycle regulation
19. Transforming growth factor β1 up-regulates p15, p21 and p27 and blocks cell cycling in G1 in human prostate epithelium
20. Expression and localization of transforming growth factor-β receptors type I and type II in the rat ventral prostate during regression
21. Apoptotic versus proliferative activities in human benign prostatic hyperplasia
22. Prostate tissue composition and response to finasteride in men with symptomatic prostatic hyperplasia
23. The role of transforming growth factor-β1, -β2, and -β3 in androgen-responsive growth of NRP-152 rat prostatic epithelial cells
24. Hormonal control of programmed cell death/apoptosis
25. Effect of transforming growth factor-β1 on proliferation and death of rat prostatic cells
26. Retroviral transduction of transforming growth factor-βl induces pleiotropic benign prostatic growth abnormalities in mouse prostate reconstitutions
27. Transforming growth factor β1 and its receptor types I and II. Comparison in human normal prostate, benign prostatic hyperplasia and prostatic carcinoma
28. Transforming growth factor beta I expression in benign and malignant prostatic tumors
29. Regressive changes in finasteride-treated human hyperplastic prostates correlate with an upregulation of TGFβ receptor expression
30. Identification of a cellular receptor for transforming growth factor-β in rat ventral prostate and its negative regulation by androgens
31. Mechanism of activation of the TGF-β receptor
32. Restoration of transforming growth factor signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis
33. Correlation between proliferation, apoptosis and angiogenesis in prostate carcinoma and their relation to androgen ablation
34. The efficacy of terazosin, finasteride or both in benign prostatic hyperplasia